KCP
CRL icon

Kera Capital Partners’s Charles River Laboratories CRL Stock Holding History

Kera Capital Partners’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$459K Sell
2,026
-145
-7% -$25.8K 0.04% 349
2026
Q1 		$374K Sell
2,171
-340
-14% -$63K 0.05% 338
2025
Q4 		$529K Buy
2,511
+108
+4% +$19.6K 0.07% 224
2025
Q3 		$376K Buy
2,403
+553
+30% +$87.8K 0.06% 232
2025
Q2 		$281K Sell
1,850
-50
-3% -$6.67K 0.06% 219
2025
Q1 		$286K Buy
1,900
+568
+43% +$95.2K 0.09% 109
2024
Q4 		$246K Buy
+1,332
New +$257K 0.07% 103

Other funds holding CRL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Kera Capital Partners's CRL Position: Q2 2026 in Review

Kera Capital Partners reduced its Charles River Laboratories (CRL) stake by 6.7% in Q2 2026, selling an estimated $25.8K and leaving 2,026 shares worth $459K. The position accounts for 0.04% of the portfolio, ranked #349.

Kera Capital Partners first reported a position in CRL in Q4 2024 and has held it in 7 quarters since. The position peaked at $529K in Q4 2025. 565 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

  • Kera Capital Partners held 2,026 shares of Charles River Laboratories worth $459K as of Q2 2026.
  • Kera Capital Partners sold 145 Charles River Laboratories shares in Q2 2026, an estimated $25.8K.
  • Charles River Laboratories made up 0.04% of Kera Capital Partners's portfolio in Q2 2026, its #349 holding.
  • Kera Capital Partners first reported a position in Charles River Laboratories in Q4 2024 and has held it in 7 quarters since.
  • Kera Capital Partners's Charles River Laboratories position peaked at $529K in Q4 2025.
  • 565 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on Kera Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.